Overview

Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

Status:
Completed

Trial end date:
2019-11-25

Target enrollment:

Participant gender:

Summary

A study to assess safety and efficacy of evolocumab (AMG-145) in paediatric subjects aged 10-17 years diagnosed with heterozygous familial hypercholesterolemia.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Evolocumab